Panelists discuss understanding institutional protocols for managing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) prophylaxis in bispecific antibody therapy, along with criteria for safely selecting patients for outpatient step-up dosing.
AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.
Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.
Pharmacists can make a significant impact by providing medication management, promoting nonpharmacologic approaches, supporting patients through life transitions.
Daily operational tasks and quality assurance measures in pharmacy compounding ensures patient safety and maintains compliance.
Ira Zackon, MD, explains where future research lies regarding the implementation of bispecific antibodies in community oncology settings.
The novel camizestrant-ribociclib combination demonstrated encouraging data in advanced, pre-treated ER+/HER2- breast cancer.
Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.
Pharmacists can help drive the successful adoption of biosimilars by developing educational programs to address provider and patient concerns.
The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.
Pharmacists are crucial skin care experts and should counsel patients on the importance of adjunct therapies like moisturizers and sunscreen when using certain medications.
The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.
Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.
Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.
Rural patients face significant barriers to health care access and affordability that contribute to poor hypertension management.
Komal Jhaveri MD, FACP, shares that the combination of imlunestrant plus abemaciclib further improved progression-free survival compared to imlunestrant alone.
Dose rounding within an acceptable range can provide cost savings and minimize waste, but requires careful interprofessional collaboration and patient education.
Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.
Pharmacists are essential members of the patient care team, leveraging technology like automated IV compounding to standardize processes.
Pharmacists play a crucial role in promoting the appropriate use of broad-spectrum antibiotics to prevent antimicrobial resistance and improve patient outcomes.
Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible.
Luca Bertamini, MD highlights the potential clinical implications of using circulating tumor cells as a biomarker in patients with newly-diagnosed multiple myeloma.
The primary challenge facing rural pharmacies include recruitment and retention of staff, the need for pharmacists to handle multiple roles and expertise, and the impact of burnout and stress.
Snehal Bhatt emphasizes the need for patient-specific risk assessment and a thoughtful approach to balancing aspirin's benefits and bleeding risks as new treatment options become available.
Pharmacists play a key role in vaccination efforts to prevent respiratory illnesses.
Panelists discuss how bispecific antibody therapies in relapsed/refractory multiple myeloma commonly present with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and increased infection risks, while talquetamab specifically exhibits distinctive adverse events including nail changes, skin reactions, and oral toxicities.
Panelists discuss how infrastructure including specialized staff training, updated protocols, enhanced monitoring systems, and comprehensive educational resources for health care providers is essential for institutions to successfully implement and optimize bispecific antibody therapies while ensuring patient safety and treatment efficacy.
Ira Zackon, MD explains his analysis of bispecific antibody utilizaton for relapsed or refractory multiple myeloma in community oncology centers.
Robert Rifkin, MD, FACP, discusses multiple abstracts featuring drugs demonstrating efficacy in patients with relapsed/refractory multiple myeloma.
Shirley D'Sa, MD, highlights the long-term efficacy and tolerability of zanubrutinib in patients with Waldenström macroglobulinemia, as seen in the long-term extension of ASPEN.
